Independent directory Public ClinicalTrials.gov records United States
Sponsor Directory

Bristol-Myers Squibb clinical trials

Sponsor pages show live ClinicalTrials.gov search results and objective aggregate stats only. They do not describe sponsor quality, reputation, or expected outcomes.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 7:28 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
2039
Shown on this page
12
Current sort
Recently updated
Sponsor scope
Bristol-Myers Squibb
Additional filters apply within this sponsor.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this sponsor

These controls apply only within Bristol-Myers Squibb. Default order is Recently updated. Add condition, therapy, location, or recruitment status to narrow this sponsor page further.

Reset sponsor filters
Clear filters
Showing 217–228 of 2,039 matching trials for sponsor Bristol-Myers Squibb.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search
Conditions
Schizophrenia
Interventions
Xanomeline and Trospium Chloride Capsules
Drug
Lead sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Industry
Eligibility
18 Years to 65 Years
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
56
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Anaheim, California + 44 more
Conditions
Squamous Cell Carcinoma of the Head and Neck, Recurrent Head and Neck Squamous Cell Carcinoma
Interventions
Interleukin-15 Superagonist (N-803), CIML NK cell Infusion, Ipilimumab, Cetuximab
Drug · Biological
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Various Advanced Cancer
Interventions
Nivolumab, Placebo
Biological · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
709 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
33
States / cities
Anchorage, Alaska • Tucson, Arizona • Clovis, California + 27 more
Conditions
Heart Failure
Interventions
BMS-986435, Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
40 Years to 85 Years
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
23
States / cities
Birmingham, Alabama • Lakewood, Colorado • Jacksonville, Florida + 18 more
Conditions
Osteosarcoma, Osteosarcoma in Children, Osteosarcoma Recurrent, Sarcoma
Interventions
Nivolumab, Azacitidine, Post Treatment Surgery
Drug · Procedure
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
Up to 39 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
22
States / cities
Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 19 more
Conditions
Gastric Cancer, Esophageal Cancer
Interventions
oxaliplatin, capecitabine
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older · Female only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Advanced Malignant Tumors
Interventions
BMS-986488, Adagrasib, Cetuximab, Nivolumab
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
437 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
4
States / cities
Hackensack, New Jersey • Allentown, Pennsylvania • Germantown, Tennessee + 1 more
Conditions
Multiple Sclerosis, Progressive Multifocal Leukoencephalopathy
Interventions
Ozanimod
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2041
U.S. locations
1
States / cities
Lawrenceville, New Jersey
Conditions
Metastatic Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8, Stage IVB Hepatocellular Carcinoma AJCC v8, Unresectable Hepatocellular Carcinoma
Interventions
IDO1 Inhibitor BMS-986205, Nivolumab
Drug · Biological
Lead sponsor
Edward Kim
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Sacramento, California
Recruiting No phase listed Observational Accepts healthy volunteers

New Assessment System in Measuring Symptom Distress in Cancer Patients

NCT00505245
Conditions
Caregiver, Health Care Provider, Malignant Neoplasm, Physician
Interventions
Interview, Quality-of-Life Assessment, Questionnaire Administration
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2031
U.S. locations
1
States / cities
Houston, Texas
Conditions
Urothelial Cancer
Interventions
Iza-bren, Cisplatin, Gemcitabine, Carboplatin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
470 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2033
U.S. locations
35
States / cities
Gilbert, Arizona • Fullerton, California • Palo Alto, California + 26 more
Conditions
Basal Cell Carcinoma
Interventions
Nivolumab, Relatlimab plus Nivolumab
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
3
States / cities
Irvine, California • La Jolla, California • San Francisco, California

About this Bristol-Myers Squibb sponsor directory page

What this page lists
U.S. ClinicalTrials.gov public records where Bristol-Myers Squibb is the lead sponsor, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results
Use the filters above to scope by condition, intervention, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Bristol-Myers Squibb trials.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, sponsor quality scoring, ranking of trials, or AI-generated medical summaries.

Related: all sponsor pages, browse by condition, browse by drug or therapy, browse by U.S. city, or open the full search for Bristol-Myers Squibb.